Details for Patent: 10,933,147
✉ Email this page to a colleague
Which drugs does patent 10,933,147 protect, and when does it expire?
Patent 10,933,147 protects AXUMIN and is included in one NDA.
Summary for Patent: 10,933,147
| Title: | Imaging of metastatic or recurrent cancer |
| Abstract: | The present disclosure relates to methods of administering [18F]-FACBC. The present disclosure also relates to use of [18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer. |
| Inventor(s): | Matthew Miller, David Gauden, David Schuster, Stefano Fanti, Cristina Nanni, Lucia Zanoni, Frode Willoch, Trond BOGSRUD, Tore Bach-Gansmo, Alessandra Musto |
| Assignee: | Blue Earth Diagnostics Ltd |
| Application Number: | US16/907,779 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,933,147
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blue Earth | AXUMIN | fluciclovine f-18 | SOLUTION;INTRAVENOUS | 208054-001 | May 27, 2016 | RX | Yes | Yes | 10,933,147 | ⤷ Start Trial | POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
